Protagen AG to Apply UNIarray(R) Platform for Biogen Idec, Inc. (Massachusetts)
Published: Mar 29, 2011
“There is an acute need to discover possible response and non-response biomarkers in MS using genomic and proteomic level markers,” said Dr. Peter Schulz-Knappe, CSO of Protagen AG. “Autoantibody signatures play an increasingly important role as a technology platform that could be used to identify patients for optimized treatment efficacy and to monitor disease progression.”
“Pharmaceutical companies recognize more and more the importance of autoantibody signatures for drug development, and Protagen provides the right technology and unique expertise for collaborations in this area”, said Dr. Stefan Müllner, CEO.
Background: UNIarray® is a unique technology platform for the development of novel diagnostics based on indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be present in several autoimmune diseases, but also in cancer and neurodegenerative disorders. The systematic and indication-specific determination of autoantibody patterns will serve as a powerful basis to address hitherto unmet diagnostic needs. UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification tools for clinical studies.
About Protagen AG - www.protagen.de
Protagen AG is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.
Dr. Stefan Müllner CEO Protagen AG Otto-Hahn-Str. 15 44227 Dortmund Tel: +49 (0) 231 9742 6300 Fax: +49 (0) 231 9742 6301 E-Mail: firstname.lastname@example.org
Bettina Franz Protagen AG Otto-Hahn-Str. 15 44227 Dortmund Tel: +49 (0) 231 9742 6300 Fax: +49 (0) 231 9742 6301 E-Mail: email@example.com